Anlotinib Hydrochloride Combined With Liposomal Doxorubicin in the Treatment of Locally Advanced or Metastatic Soft Tissue Sarcoma (ALTER-S001)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03880695 |
|
Recruitment Status :
Recruiting
First Posted : March 19, 2019
Last Update Posted : March 21, 2019
|
Sponsor:
Peking University People's Hospital
Collaborators:
Peking University Shougang Hospital
Beijing Cancer Hospital
Tianjin Medical University Cancer Institute and Hospital
First Hospital of Jilin University
Hunan Cancer Hospital
Ruijin Hospital
Liaoning Tumor Hospital & Institute
Information provided by (Responsible Party):
GUO WEI, Peking University People's Hospital
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | April 2021 |
| Estimated Study Completion Date : | May 2021 |